ESTRO 2024 - Abstract Book

S420

Brachytherapy - Urology

ESTRO 2024

Distant intra-prostatic recurrence was minimal in both cohorts, though this was likely limited by the timing of the mpMRI at 1-2 years post-salvage.

Keywords: salvage, prostate, brachytherapy

References:

1. Corkum MT et al. A Prospective Study of Magnetic Resonance Imaging-guided Focal Salvage High-dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients. Pract Radiat Oncol. 2022 Nov Dec;12(6):e531-e537.

2. Chung HT et al. MR-assisted salvage HDR prostate brachytherapy with intra-prostatic boost: a prospective study. Radiat Oncol. 2023 May;182(S1):S518.

2085

Proffered Paper

Impact of biochemical failure on overall survival in low comorbidity high risk prostate cancer

Visus Ignacio 1 , Martínez Irene 1 , Marta Barrado 1 , Amaya Sola 1 , Flamarique Sonia 1 , Maria Isabel Martínez 1 , Mikel Rico 1 , Patricia Lorenzana 1 , Paola Jablonska 1 , Erkuden Burillo 1 , M.Ujue Ruiz 1 , Libe Almondarain 1 , Darwin Pozo 1 , Naiara Fuentemilla 2 , Santiago Pellejero 2 , Raquel Villanueva 3 , Noelia Garcia 3 , Elena Villafranca 1 , Enrique Martinez 1 1 University Hospital of Navarre, Radiation Oncology, Pamplona, Spain. 2 University Hospital of Navarre, Medical Physics, Pamplona, Spain. 3 University Hospital of Navarre, Oncology Nursing, Pamplona, Spain

Purpose/Objective:

Treatment options with biochemical failure (BCF) superiority but without benefit in overall survival (OS), such as brachytherapy boost , are discussed in prostate cancer management. Comorbidity has been described as a competing risk of death that could affect overall survival benefit in these treatments. We aim to assess the impact of comorbidity in the association between BCF and OS in a high-risk and very-high-risk prostate cancer series treated with HDR brachytherapy boost (HDR-BT) or exclusive external beam radiotherapy (EBRT).

Material/Methods:

We extract data from the clinical record of each patient in the series in order to collect all the pharmacological prescriptions at least 5 years after treatment. Seven groups of drugs were identified: antihypertensive, antithrombotics, antiplatelets, statins, antiarrhythmics, antidiabetics and bronchodilators.